Zaia John A, Sun Joel Y, Gallez-Hawkins Ghislaine M, Thao Lia, Oki Arisa, Lacey Simon F, Dagis Andrew, Palmer Joycelynne, Diamond Don J, Forman Stephen J, Senitzer David
CMV Laboratory in the Department of Virology, City of Hope, Duarte, California, USA.
Biol Blood Marrow Transplant. 2009 Mar;15(3):315-25. doi: 10.1016/j.bbmt.2008.11.030.
It has been shown that activating killer Ig-like receptor (aKIR) genes are important for control of cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation (HCT). To date, using the broad classification of KIR haplotypes A and B, the precise role of individual KIR genes in the control of infection cannot be discerned. To address this, a consecutive case series of 211 non-T cell-depleted HCT patients all at risk for CMV were monitored biweekly for CMV DNA in plasma by quantitative polymerase chain reaction (Q-PCR) and at intervals for CMV-specific T cell immunity. Comparing patients with CMV reactivation (n = 152) to those with no reactivation (n = 59), the presence of specific aKIR haplotypes in the donor, but not in the recipient, were associated with protection from CMV reactivation and control of peak plasma CMV DNA (P < .001). A donor aKIR profile, predictive for low risk of CMV reactivation, contained either aKIR2DS2 and aKIR2DS4 or had >/=5 aKIR genes. Neither donor nor recipient inhibitory KIR (iKIR) played a role in a protective effect. CD4(+)- and CD8(+)-specific CMV immunity did not explain reduced CMV infection. The initial control of CMV infection after HCT is managed by aKIR functions, and donor aKIR haplotypes deserve further evaluation in donor selection for optimized HCT outcome.
研究表明,激活杀伤细胞免疫球蛋白样受体(aKIR)基因对于控制造血细胞移植(HCT)后巨细胞病毒(CMV)的重新激活很重要。迄今为止,使用KIR单倍型A和B的宽泛分类,无法辨别单个KIR基因在控制感染中的精确作用。为了解决这个问题,对211例均有CMV感染风险的非T细胞去除的HCT患者连续病例系列进行了研究,通过定量聚合酶链反应(Q-PCR)每两周监测一次血浆中的CMV DNA,并定期监测CMV特异性T细胞免疫。将发生CMV重新激活的患者(n = 152)与未发生重新激活的患者(n = 59)进行比较,供体中而非受体中特定aKIR单倍型的存在与预防CMV重新激活及控制血浆CMV DNA峰值相关(P <.001)。预测CMV重新激活低风险的供体aKIR谱包含aKIR2DS2和aKIR2DS4,或具有≥5个aKIR基因。供体和受体的抑制性KIR(iKIR)在保护作用中均未发挥作用。CD4(+)和CD8(+)特异性CMV免疫不能解释CMV感染的减少。HCT后CMV感染的初始控制由aKIR功能管理,供体aKIR单倍型在供体选择中值得进一步评估,以优化HCT结果。